v3.26.1
Equity Method Investments (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Apr. 30, 2024
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Aug. 31, 2024
Schedule Of Equity Method Investments [Line Items]              
Loss from equity method investment   $ 6,435 $ 20,189 $ 24,718 $ 35,745    
Equity method investments   55,095   55,095   $ 79,972 [1]  
Prepaid expenses and other current assets   65,652   65,652   44,070 [1]  
Research and development   149,448 111,231 276,084 222,662    
Other current liabilities [2]   192,186   192,186   120,222 [1]  
Gondola Bio, LLC | Transition Service Agreement And Sublease Agreement              
Schedule Of Equity Method Investments [Line Items]              
Operating expenses   600 1,900 2,500 2,700    
Prepaid expenses and other current assets   3,400   3,400   4,500  
Other current liabilities   800   800   1,500  
Gondola Bio, LLC | Transition Service Aggrement              
Schedule Of Equity Method Investments [Line Items]              
Research and development   $ 400 500 $ 400 1,200    
Gondola Bio, LLC              
Schedule Of Equity Method Investments [Line Items]              
Equity ownership percentage approximately   13.60%   13.60%     45.50%
Loss from equity method investment   $ 0 9,100 $ 6,400 15,900    
Equity method investments   0   0   6,400  
Gondola Bio, LLC | Transition Service Agreement And Sublease Agreement              
Schedule Of Equity Method Investments [Line Items]              
Other income   $ 2,200 2,700 $ 4,700 5,400    
BridgeBio Oncology Therapeutics, Inc.              
Schedule Of Equity Method Investments [Line Items]              
Equity ownership percentage approximately   18.20%   18.20%      
Loss from equity method investment   $ 6,200 $ 11,100 $ 17,900 $ 19,800    
Equity method investments   54,600   54,600   72,500  
Payment for private equity financing with external investors $ 200,000            
Percentage of ownership reduced for private equity financing 37.90%            
BridgeBio Oncology Therapeutics, Inc. | Level 1              
Schedule Of Equity Method Investments [Line Items]              
Investors contribution fair value   $ 111,200   $ 111,200   $ 182,700  
[1] The condensed consolidated balance sheet as of December 31, 2025 is derived from the audited consolidated financial statements as of that date.
[2] Including related party amounts of $5,626 and $2,003 as of June 30, 2026 and December 31, 2025, respectively (as described in Note 9).